The short version of incretin mimetic fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-10-23. Anything still debated is marked as such rather than presented as settled.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1, a hormone released from intestinal L cells after food intake. The molecule is a 31-amino-acid backbone modified at three positions to resist cleavage by dipeptidyl peptidase-4, the enzyme that degrades native GLP-1 within minutes. A lysine residue at position 26 carries a linker and a C18 fatty diacid, which promotes binding to serum albumin and slows renal clearance. These changes extend the circulating half-life from roughly two minutes to about one week in humans.
The sequence incorporates alpha-aminoisobutyric acid at position 8, replacing the alanine found in the natural hormone. This substitution blocks the primary DPP-4 recognition site and contributes most of the enzymatic stability. Albumin binding further protects the peptide and reduces the frequency of administration required to maintain active plasma levels. Because the fatty acid chain increases lipophilicity, the compound is formulated as a solution rather than a simple aqueous buffer. Researchers describe the design as an incremental optimization of earlier GLP-1 analogs rather than a wholly new scaffold.
Reported molecular weight is approximately 4113.6 daltons for the free base, and the peptide is supplied as a lyophilized powder or in buffered liquid form depending on the intended use. It is freely soluble in water when formulated with appropriate excipients, though the unconjugated peptide shows limited stability at neutral pH over long periods. Analytical characterization typically relies on reversed-phase high-performance liquid chromatography and mass spectrometry. Purity specifications for research-grade material commonly exceed ninety-five percent by area. Isotopic and impurity profiles differ between suppliers.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1, a hormone released from intestinal L-cells after food intake. It contains 31 amino acids and differs from native GLP-1 through modifications that slow enzymatic breakdown. The peptide was developed to extend the short circulating half-life of endogenous GLP-1, which is measured in minutes. Researchers introduced the compound in the early 2010s. Two backbone changes and a fatty acid side chain define its structure, distinguishing it from earlier GLP-1 receptor agonists.
The compound binds the GLP-1 receptor on pancreatic beta cells and other tissues, activating a G-protein signaling cascade that raises intracellular cyclic AMP. This action increases glucose-dependent insulin secretion when blood glucose is elevated, while binding also slows gastric emptying and reduces glucagon release. In the central nervous system, receptor activation in the hypothalamus and brainstem contributes to reduced appetite. The fatty acid chain binds albumin, which protects the peptide from renal filtration and enzymatic degradation. This albumin binding is central to its extended circulation time.
Native GLP-1 is degraded rapidly by dipeptidyl peptidase-4. Semaglutide resists this cleavage because alanine at position 8 is replaced by alpha-aminoisobutyric acid. A second substitution at position 34 introduces arginine, which further stabilizes the peptide. The most distinctive modification is a spacer and C18 fatty diacid attached at lysine 26, enabling strong albumin affinity. These three changes together produce a half-life measured in days rather than minutes, and the same structural logic underlies other long-acting analogs in this class.
| Property | Value | Notes |
|---|---|---|
| Molecular formula (free base) | C187H291N45O59 | Approximate; salt and hydrate forms differ |
| Molecular weight | ~4113.6 Da | Varies with counterion and hydration |
| Appearance | White to off-white powder | Lyophilized research material |
| Solubility class | Freely soluble in water | As formulated; native peptide less stable near neutral pH |
| Typical storage | 2 to 8 degrees Celsius | Protect from light; avoid repeated freeze-thaw |
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
Lyophilized peptide material is typically stored at or below -20 °C, with -80 °C used for longer-term archives. Vials should remain sealed and desiccated because moisture promotes aggregation and hydrolysis. Repeated freeze-thaw cycles are avoided since they can alter peptide conformation and reduce recovery. Once reconstituted, solutions are generally kept at 2-8 °C and used within a defined window. Stability beyond those windows depends on buffer composition and concentration, and exact limits are product-specific rather than universal.
Identity and purity are assessed with reversed-phase high-performance liquid chromatography, which separates the peptide from related impurities by hydrophobicity. Mass spectrometry confirms molecular weight and detects truncation or modification products. Peptide mapping after enzymatic digestion verifies the amino acid sequence. Quantitation is often performed by LC-MS/MS or by immunoassay, and the two approaches can give different values because they measure different things. Method validation parameters such as accuracy, precision, and limit of quantitation are reported alongside results.
Certificate of analysis documents from suppliers typically report purity by chromatographic area, water content, and counter-ion identity. Independent verification is advisable because reported values can be generated under differing conditions. Impurity profiles matter for research use, where aggregates, deamidation products, and residual solvents may influence experimental results. Container, lot, and chain-of-custody records support traceability. Analytical results are method-dependent, so comparisons between laboratories require the same procedure and reference standards.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released after nutrient intake. The molecule contains 31 amino acid residues and differs from the native sequence at several positions. A non-natural residue at position eight resists the enzyme that normally truncates the hormone, while a lysine-linked fatty diacid side chain promotes binding to serum albumin. These two modifications extend the circulating half-life from minutes to roughly one week. The peptide is produced by solid-phase synthesis followed by selective acylation, and its identity and purity are confirmed by spectrometric and chromatographic techniques.
The primary target is the GLP-1 receptor, a class B G protein-coupled receptor expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises intracellular cyclic AMP, which potentiates glucose-dependent insulin secretion and lowers glucagon release when blood glucose is elevated. Signalling in the hypothalamus and brainstem is associated with reduced appetite and slower gastric emptying. Because the insulinotropic effect depends on prevailing glucose levels, the hypoglycaemic risk of the peptide alone is described as low in most study settings. The relative contribution of peripheral and central actions remains an active research question.
Large randomised trials in adults with type 2 diabetes and in adults with obesity have reported reductions in body weight and improvements in several cardiovascular risk markers. One outcome trial found a lower incidence of major adverse cardiovascular events in participants with diabetes and established cardiovascular disease. Gastrointestinal effects such as nausea and vomiting are the most frequently reported adverse events and often diminish over time. Changes in lean body mass during weight loss are an area of ongoing investigation. Effects in adolescents and in pregnancy are less well characterised, and current labelling advises against use during pregnancy.
The divisions between the elite and the lawless led to the formation of a Cossack army, beginning in 1667 under Stenka Razin, and ultimately to the failure of Razin's rebellion. Stenka Razin was born into an elite Cossack family, and had made many diplomatic visits to Moscow before organizing his rebellion. The Cossacks were Razin's main supporters, and followed him during his first Persian campaign in 1667, plundering and pillaging Persian cities on the Caspian Sea. They returned in 1669, ill and hungry, tired from fighting, but rich with plundered goods. Russia tried to gain support from the old Cossacks, asking the ataman, or Cossack chieftain, to prevent Razin from following through with his plans. But the ataman was Razin's godfather, and was swayed by Razin's promise of a share of expedition wealth. His reply was that the elite Cossacks were powerless against the band of rebels. The elite did not see much threat from Razin and his followers either, although they realized he could cause them problems with the Muscovite system if his following developed into a rebellion against the central government. Razin and his followers began to capture cities at the start of the rebellion, in 1669. They seized the towns of Tsaritsyn, Astrakhan, Saratov, and Samara, implementing democratic rule and releasing peasants from slavery as they went. Razin envisioned a united Cossack republic throughout the southern steppe, in which the towns and villages would operate under the democratic, Cossack style of government.
This concept of the human body is opposed to the European duality of a separate mind and body. It is critical for scholars to understand the fundamental differences in concepts of the body in order to connect the medical theory of the classics to the "human organism" it is explaining. Chinese scholars established a correlation between the cosmos and the "human organism". The basic components of cosmology, qi, yin yang and the Five Phase theory, were used to explain health and disease in texts such as Huangdi neijing. Yin and yang are the changing factors in cosmology, with qi as the vital force or energy of life. The Five Phase theory (Wuxing) of the Han dynasty contains the elements wood, fire, earth, metal, and water. By understanding medicine from a cosmology perspective, historians better understand Chinese medical and social classifications, such as gender, which was defined by a domination or remission of yang in terms of yin. These two distinctions are imperative when analyzing the history of traditional Chinese medical science. A majority of Chinese medical history written after the classical canons comes in the form of primary source case studies where academic physicians record the illness of a particular person and the healing techniques used, as well as their effectiveness.
The word "parsley" is a merger of Old English petersilie (which is identical to the contemporary German word for parsley: Petersilie) and the Old French peresil. Both of these names are derived from Medieval Latin petrosilium, from Latin petroselinum, which is the latinization of the Greek πετροσέλινον, petroselinon, 'rock-celery', from πέτρα, petra, 'rock, stone' and σέλινον, selinon, 'celery'. Mycenaean Greek se-ri-no, in Linear B, is the earliest attested form of the word selinon.
Sources: en.wikipedia.org
embryo The developing organism that represents the earliest stages of development in all sexually reproducing multicellular organisms, traditionally encompassing the period after fertilization of an egg cell and formation of the zygote but prior to birth, hatching, or metamorphosis. During this period, known as embryonic development, the single-cell zygote is transformed by repeated cell divisions and rearrangements into a series of increasingly complex multicellular structures. For humans, the term "embryo" is only used until the ninth week after conception, after which time the embryo is known as a foetus; for most other organisms, including plants, "embryo" can be used more broadly to describe any early stage of the life cycle.
==== Absorption and metabolism ==== Morphine can be taken orally, sublingually, bucally, rectally, subcutaneously, intranasally, intravenously, intrathecally or epidurally and inhaled via a nebulizer. As a recreational drug, it is becoming more common to inhale ("Chasing the Dragon"), but, for medical purposes, intravenous (IV) injection is the most common method of administration. Morphine is subject to extensive first-pass metabolism (a large proportion is broken down in the liver), so, if taken orally, only 40% to 50% of the dose reaches the central nervous system. Resultant plasma levels after subcutaneous (SC), intramuscular (IM), and IV injection are all comparable. After IM or SC injections, morphine plasma levels peak in approximately 20 min, and, after oral administration, levels peak in approximately 30 min. Morphine is metabolised primarily in the liver and approximately 87% of a dose of morphine is excreted in the urine within 72 h of administration. Morphine is metabolized primarily into morphine-3-glucuronide (M3G) and morphine-6-glucuronide (M6G) via glucuronidation by phase II metabolism enzyme UDP-glucuronosyl transferase-2B7 (UGT2B7). About 60% of morphine is converted to M3G, and 6% to 10% is converted to M6G. Not only does the metabolism occur in the liver but it may also take place in the brain and the kidneys. M3G does not undergo opioid receptor binding and has no analgesic effect. M6G binds to μ-receptors and is half as potent an analgesic as morphine in humans.
in light of background scientific knowledge, the antecedent plausibility of TT is sufficiently low that any methodological flaw in a study will always provide a more plausible explanation for any positive findings. Emily Rosa, at nine years of age, conceived and executed a study on therapeutic touch. With the help of Quackwatch's Stephen Barrett and the assistance of her mother, Linda Rosa, and her step-father, Larry Sarner, Emily became the youngest researcher to have a paper accepted by the Journal of the American Medical Association (JAMA), which debunked the claim of therapeutic touch practitioners that they can reliably sense a "Human Energy Field." Twenty-one practitioners of therapeutic touch participated in her study. The practitioners sat on one side of a cardboard screen, while Emily sat on the other. The practitioners then placed their hands through holes in the screen. Emily flipped a coin to determine which of each practitioner's hands she would place hers over (approximately 4-5 inches above the subject's hand). The practitioners then were to say where her hand was by sensing her biofield. Although all of the participants had asserted that they would be able to do this, the actual results did not support therapeutic touch's fundamental claim. The practitioners had succeeded in locating Emily's hand 44% of the time, a rate lower than, though within the range of, mere chance. The JAMA editor George D.
In September 2015, Jim Reid announced that the band were recording their first studio album since 1998. The album titled Damage and Joy was produced by Youth and released on 24 March 2017. On 24 August 2017, Bobby Gillespie joined the band on drums for three Psychocandy songs during their performance at Vilar de Mouros Festival in Portugal. In autumn 2018, they opened for Nine Inch Nails' "Cold and Black and Infinite" North American tour. The band announced a Darklands tour of Europe in March and April 2020, which was ultimately postponed to November and December 2021. In June 2021, the band sued Warner Music Group for control of their debut album, Psychocandy, and later albums, and seeking $2.55 million in damages. Under Section 203 of the United States' Copyright Act of 1976, artists may reclaim the rights to their recordings after 35 years, provided that they serve timely and proper notice upon the current record label. The case was settled out of court in March 2023 On 29 November 2023, the band released "Jamcod", the lead single from their eighth album, Glasgow Eyes, which was released on 22 March 2024. On 24 September 2026, the band was announced as a headliner for Something In The way festival 2027
Sources: en.wikipedia.org
=== Long-term complications === In addition to the acute complications of diabetes, long-term hyperglycemia results in damage to the small blood vessels throughout the body. This damage tends to manifest particularly in the eyes, nerves, and kidneys, causing diabetic retinopathy, diabetic neuropathy, and diabetic nephropathy, respectively. In the eyes, prolonged high blood sugar causes the blood vessels in the retina to become fragile. People with type 1 diabetes also have an increased risk of cardiovascular disease, which is estimated to shorten the life of the average type 1 diabetic by 8–13 years. Cardiovascular disease as well as neuropathy may have an autoimmune basis, as well. Women with type 1 DM have a 40% higher risk of death as compared to men with type 1 DM. About 12 percent of people with type 1 diabetes have clinical depression. About 6 percent of people with type 1 diabetes also have celiac disease, but in most cases there are no digestive symptoms or are mistakenly attributed to poor control of diabetes, gastroparesis, or diabetic neuropathy. In most cases, celiac disease is diagnosed after the onset of type 1 diabetes. The association of celiac disease with type 1 diabetes increases the risk of complications, such as retinopathy and mortality. This association can be explained by shared genetic factors, and inflammation or nutritional deficiencies caused by untreated celiac disease, even if type 1 diabetes is diagnosed first.
=== Contestants === 1st - Renee Loranger, Pastry Chef from Waveland, Mississippi 2nd - Guillermo Salinas from Jackson, Mississippi 2nd - Adina Schaefer, Executive Pastry Chef from Los Angeles, California 4th - Megan Baker, Bakery Owner from Minneapolis, Minnesota 5th - Ashley Wong from Fremont, California 6th - Wes Dills from Austin, Texas 7th - Sherelle Morrison from Indian Land, South Carolina 8th - Jocelyn Jung, Bakery Owner from San Diego, California 9th - Anirudh Mamtora from Cherry Hill, New Jersey 9th - Nicole Proske from Miami, Florida 11th - Steven Sechoka from Boston, Massachusetts 12th - Paul Allicock from Miami, Florida
==== Rwanda ==== Zipline operates two distribution centers in Rwanda. Zipline began deliveries at its first distribution center in Muhanga in October 2016. In 2018, the Rwandan government signed a new deal to build a second distribution center near Kayonza, in the eastern part of the country. This deal expanded Zipline's service to include smaller health centers and hospitals and deliver vaccines and other medical products and blood products. Zipline opened the Kayonza distribution center in December 2018. The company hoped this would bring coverage to 80 percent of the country. Rwanda has mountainous geography and poor road conditions, making an aerial delivery system more efficient than the use of land vehicles. The cost of delivery via drone is comparable to that of delivery by road, especially in emergencies. A 2022 study found that Zipline's service in Rwanda leads to faster delivery times relative to existing ground transportation and less blood component wastage in health facilities. The study found that Zipline's drone delivery service in Rwanda shortened blood product delivery times by 61 percent, reduced blood unit expirations by 67 percent, and was frequently used in response to medical emergencies, with 43 percent of orders being emergency orders.
Sources: en.wikipedia.org
It is a modified version of the natural hormone, with three amino acid changes and a fatty acid side chain added. These edits extend its half-life from minutes to about one week. The core receptor activity is retained.
Both deliver the same active peptide and act on the same receptor. The tablet includes an absorption enhancer because peptides are poorly taken up intact from the gut. Bioavailability of the oral route is substantially lower, so the two are not dose-equivalent.
No, it is entirely synthetic and does not occur in nature. Native GLP-1 is produced in the gut and pancreas, but the analog is manufactured by chemical synthesis or recombinant methods. Traces of the analog are not expected in people who never received it.
It is a synthetic analog of GLP-1 produced through medicinal chemistry to resist enzymatic degradation. The design goal was longer circulation than the native hormone.